Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Technology Report
  • Published:

An International Perspective

Bio/Technology volume 1, pages 33–36 (1983)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Quantitative data given in this paper are derived from patents reported in the biweekly periodical, Biotechnology Patent Digest, OMEC Publishing Co., McLean, VA.

  2. Science Indicators 1980, National Science Foundation, p. 18–21, 1981.

  3. The percentages given do not include U.S. inventors assigning their rights to foreign organizations.

  4. While there are examples of foreign inventors assigning the rights to U.S. corporations in the 1982 biotechnology patents covered, the practice is not significant (less than 10 examples). Also, equal examples exist of U.S. inventors assigning their rights to foreign corporations. Again, the total number is not significant.

  5. Merck and Miles are identified as U. S. companies because the patents issued to them were assigned to the U.S. organization. However, Merck is also based in West Germany and Miles is a subsidiary of Bayer AG, a West German company.

  6. The author recognizes that some patents from the new genetic engineering companies may have been filed but not yet issued. Indeed, a few have been filed at other patent offices, especially the European Patent Office. Also, the U.S. PTO has been quite efficient in issuing most biotechnology patents within 2 years after filing. Some patents have been issued in less than a year, but there are also cases which required a longer time period.

Download references

Author information

Author notes

  1. Oskar R. Zaborsky, Ph.D., is program director at the National Science Foundation and founding editor of Biotechnology Patent Digest.

    • Oskar R. Zaborsky
Authors
  1. Oskar R. Zaborsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zaborsky, O. An International Perspective. Nat Biotechnol 1, 33–36 (1983). https://doi.org/10.1038/nbt0383-33b

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0383-33b

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing